Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.
暂无分享，去创建一个
J. Tie | M. Peeters | S. Siena | T. Yoshino | S. Lonardi | A. Takashima | T. André | J. Strickler | K. Yamaguchi | Y. Komatsu | Kojiro Kobayashi | K. Raghav | H. Kawakami | M. Di Bartolomeo | M. Van den Eynde | Q. Yan | T. Kamio | D. Barrios | T. Kato | C. Grávalos Castro